The cancer monoclonal antibodies market comprises of sales of monoclonal antibodies used for cancer therapy and related services by entities that create monoclonal antibodies for cancer treatment. Because they bind to the proteins on cancer cells' surfaces, monoclonal antibodies are highly selective molecules for cancer cells, triggering an immune response. Traditional cancer treatments such as chemotherapy and radiotherapy have adverse effects such as toxicity. Monoclonal antibodies are a new and effective approach of treating cancer cells that are targeted to individual cells. They are employed because of their selectivity and low toxicity.
MARKET SCOPE
The "Global Cancer Monoclonal Antibodies Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the cancer monoclonal antibodies market with detailed market segmentation by type, therapies, application, and geography. The report provides key statistics on the market status of the leading cancer monoclonal antibodies market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type, the market is bifurcated into murine antibodies, chimeric antibodies, and humanized antibodies
- Based on therapies, the market is bifurcated into bevacizumab, rituximab, trastuzumab, cetuximab, panitumumab, and other monoclonal antibody therapies
- Based on application, the market is bifurcated into breast cancer, blood cancer, liver cancer, colorectal cancer, lung cancer, and others
MARKET DYNAMICS
Drivers:
- Growing prevalence of cancer
- Rising investment in R&D of genomic studies
Restraints:
- Rise in the failures of mAbs in clinical trials
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The cancer monoclonal antibodies market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the cancer monoclonal antibodies market in these regions.
IMPACT OF COVID-19 ON CANCER MONOCLONAL ANTIBODIES MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the cancer monoclonal antibodies market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from cancer monoclonal antibodies market are anticipated to lucrative growth opportunities in the future with the rising demand for health coach in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the cancer monoclonal antibodies market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Amgen Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Johnson and Johnson Services, Inc.
- Novartis AG
- Eli Lilly and Company
- Spectrum Pharmaceuticals, Inc.
- Pfizer Inc.